Glypican-3 (Gpc3), a cell surface-linked heparan sulfate proteoglycan is highly expressed during embryogenesis and is involved in organogenesis. Its exact biological function remains unknown. We have studied the expression of Gpc3 in fetal and adult liver, in liver injury models of activation of liver progenitor cells: D-galactosamine and 2-acetylaminofluorene (2-AAF) administration followed by partial hepatectomy (PH) (2-AAF/PH); and in the Solt-Farber carcinogenic model: by initiation with a single dose of diethylnitrosamine and promotion with 2-AAF followed by PH treatment. Gpc3 expression was studied using complementary DNA microarrays, reverse transcriptase-polymerase chain reaction, in situ hybridization (ISH); ISH combined with immunohistochemistry (IHC) and immunofluorescent microscopy. We found that Gpc3 is highly expressed in fetal hepatoblasts from embryonic days 13 through 16 and its expression gradually decreases towards birth. Dual ISH with Gpc3 and a-fetoprotein (AFP) probes confirmed that only hepatoblasts and no other fetal liver cells express Gpc3. At 3 weeks after birth the expression of Gpc3 mRNA and protein was hardly detected in the liver. Gpc3 expression was highly induced in oval cell of D-gal and 2-AAF/PH treated animals. Dual ISH/IHC with Gpc3 riboprobe and cytokeratin-19 (CK-19) antibody revealed that Gpc3 is expressed in activated liver progenitor cells. ISH for Gpc3 and AFP performed on serial liver sections also showed coexpression of the twooncofetal proteins. FACS isolated oval cells with anti-rat Thy1 revealed expression of Gpc3. Gpc3 expression persists in atypical duct-like structures and liver lesions of animals subjected to the Solt-Farber model of initiation and promotion of liver cancer expressing CK-19. In this work we report for the first time that the oncofetal protein Gpc3 is a marker of hepatic progenitor cells and of early liver lesions. Our findings show further that hepatic progenitor/oval cells are the target for malignant transformation in the Solt-Farber model of hepatic carcinogenesis.
Hepatic progenitor/oval cells proliferate in the liver after acute or chronic injury when the regenerative capacities of hepatocytes are compromised. 1 These cells, the progeny of putative stem cells, behave like bipotential progenitor cells capable of differentiation into mature hepatocytes and biliary epithelial cells, recapitulating hepatoblast differentiation during fetal development. [2] [3] [4] There is increasing evidence that hepatic progenitor/oval cells can undergo malignant transformation and give rise to hepatocellular carcinoma and cholangiocarcinomas (see Sell 5 and Roskams et al 6 ).
Glypicans are heparan sulfate proteoglycans that are attached at their C-terminus to the exocytoplasmic surface of the cell membrane by a glycosylphosphatidylinositol anchor and carry a glycosaminoglycan inserted close to the site of attachment. 7, 8 Six glypicans are identified in mammals and two of them, glypican-4 and -6, are expressed in adult liver, shown by Northern blot analysis of total liver RNA. 9, 10 The expression of glypicans is developmentally regulated during embryogenesis, manifesting a specific spatial and temporal pattern. The third member of this family, glypican-3 (Gpc3), is an Xlinked gene with a core protein of approximately 69 kDa. 11 Mutations in the human GPC3 gene cause Simpson-Golabi-Behmel syndrome, associated with pre-and postnatal tissue overgrowth, increased risk of embryonic tumors during early childhood, and numerous visceral and skeletal anomalies. 12 Gpc3-deficient mice exhibit the specific characteristics described in Simpson-Golabi-Behmel syndrome patients: developmental overgrowth, perinatal death, cystic and dysplastic kidneys and abnormal lung development. 13, 14 These studies showed that Gpc3 participates in regulation of cell proliferation and apoptosis during morphogenesis. It was found that Gpc3 is highly expressed in the mouse embryo, especially in mesoderm-derived tissues. In the endoderm, the transcripts were observed on 8.5 dpc and in the liver from 13.5 until 18.5 dpc but not in adult liver. 15 It was also reported that Gpc3 modulates growth factor signaling during morphogenesis and that this effect is elicited by binding of fibroblast growth factor-2, bone morphogenetic protein (BMP)-4, BMP-7 and WNT to the heparan sulfate side chains of the core protein.
14, [16] [17] [18] It was found that Gpc3 is expressed in hepatocellular carcinomas. [19] [20] [21] [22] [23] [24] In cancer cells, the mature form of Gpc3 is processed releasing the NH2-truncated protein of 40 kDa into the medium. The soluble form of Gpc3 was also identified in the serum of patients with hepatocellular carcinomas, [22] [23] [24] which can be used as a serological test for the diagnosis of hepatocellular carcinomas (see Yamauchi et al, 24 Filmus and Capurro 25 ). Studying the gene expression profile of liver epithelial progenitor cells using complementary DNA (cDNA) microarrays, we found that Gpc3 mRNA is overexpressed in rat fetal hepatoblasts and downregulated in adult hepatocytes. We found further that Gpc3 is differentially expressed in progenitor/oval cells that proliferate in different models of liver injury. Gpc3 expression persists in oval cells and in liver lesions that develop in animals subjected to a carcinogenic regimen. A preliminary report of this work was presented at the Annual Meeting of ISSCR. 26 
Materials and methods

Animals, Plasmids and Reagents
Sprague-Dawley male (180 g body weight) and pregnant female rats at 13, 14, 15, 16, 17, 18 and 21 embryonic day were purchased from Taconic Farms (German Town, NY, USA). All studies with animals were conducted under the protocol approved by the Animal Care Institute of the Albert Einstein College of Medicine.
Rat specific Gpc3 probe was generated by cloning of a 289 bp long RT-PCR product in pCR4-TOPO (Invitrogen, Carlsbad, CA, USA); pBAF 800, which contains 800 bp from a-fetoprotein (AFP) messenger RNA (mRNA), was used as described, previously. 27 2-Acetylaminofluorene (2-AAF) pellets (35 mg/ tablet; 14 days release period) were purchased from Innovative Research of America (Sarasota, FL, USA). All other materials and reagents were purchased either from Sigma-Aldrich (St Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA), unless otherwise noted.
Antibodies
For immunofluorescent (IF) analysis anti-human Gpc3 antibody (cat num AF2119) prepared in sheep and recognizing the whole molecule was purchased from R&D Systems (Minneapolis, MN, USA) and used at dilution 1:50. Anti-bovine glial fibrillary acidic protein antibody (GFAP) (cat num G560A) prepared in rabbits was purchased from Promega (Madison, WI, USA) and used at dilution 1:200. Anti-human cytokeratin-19 (CK-19) monoclonal antibody (cat num NCL-CK19) was from Novocastra (Newcastle upon Tyne, UK) and used at dilution 1:100. Polyclonal anti-desmin antibody (cat num 29593) prepared in rabbit was from AnaSpec Inc. (San Jose, CA, USA) and used at dilution 1:200. Rabbit polyclonal anti-rat laminin (cat num Z 0097) was purchased from Dako North America, Inc. (Carpinteria, CA, USA). Monoclonal OV6 antibody was a generous gift from Dr S Sell. Rabbit polyclonal anti-human protein disulfide isomerase (PDI) was a generous gift from Dr R Stockert. All secondary antibodies for IF microscopy prepared in donkeys were purchased from Jackson Immunoresearch Laboratories (West Grove, PA, USA) and used at dilution 1:100.
For cell sorting monoclonal anti-rat CD45 PE (cat num CL009PE) and anti-rat Thy1 (CD90) FITC (cat num CL005F) were purchased from Cedarlane (Burlington, NC, USA) and used at dilution 1:50. For magnetic beads sorting polyclonal rabbit antihuman platelet-derived growth factor receptor beta (PDGFR-b) (cat num PC17) was purchased from Calbiochem (San Diego, CA, USA) and used at dilution 1:10 for stellate cells isolation. Anti-rabbit IgG microbeads were purchased from Miltenyi Biotec (Auburn, CA, USA).
Liver Injury Models
Two models for activation and proliferation of oval cells were used in this work: 2-AAF treatment in combination with partial hepatectomy (PH) (2-AAF/ PH) and D-galactosamine (D-gal) induced liver injury described previously. 28 2-AAF pellets were implanted subcutaneously and 7 days later PH was performed. The animals were killed and the livers taken on day 2, 4, 6, 8, 10, 12, 14, 16, 20 and 30 after PH. D-Gal was injected intraperitoneally at a dose of 100 mg/100 g body weight and the livers taken on day 1, 2, 3, 5 and 10 after injury. Five animals were subjected to the Solt-Farber carcinogenic (SFC) protocol for inducing hyperplastic liver lesions. 29 Diethylnitrosamine was injected intraperitoneally at a dose of 2 mg/100 g body weight. After 2 weeks, two 2-AAF pellets were implanted subcutaneously and after another week PH was performed. Livers from these animals were collected 2, 5 and 9 months after PH.
Isolation of Hepatoblasts and Nonparenchymal Cells
Cell suspensions from rat fetal liver were prepared as reported previously. 30 The cells were plated on gelatin-coated dishes at a density of 20 Â 10 6 cells per 10-cm plate and were allowed to attach for 16 h, unattached cells were removed by washing with phosphate buffer saline (PBS).
Nonparenchymal liver cells (NPC) were isolated from D-gal and 2-AAF/PH-treated animals. Livers were taken on day 5 after D-gal treatment and day 10 after the surgery in 2-AAF/PH protocol. Livers at this time point showed the highest number of transit amplifying progenitor cells. Cell fractionation was performed as described previously 31 with some modifications. Rat livers were perfused with EGTA, followed by collagenase type I (Worthington Biochemical Corp., Freehold, NJ, USA). The livers were excised, minced and suspended in modified Hanks' balanced salt solution (HBSS). Cell suspension was filtered through 80-mm nylon mesh, centrifuged for 2 min at 50 g in the cold and the pellet (parenchymal fraction) was discarded. The supernatant containing the NPC was centrifuged for 10 min at 300 g in the cold. The NPC were suspended in HBSS containing 0.1% collagenase type I and 0.004% DNAseI (Roche Applied Science, Indianapolis, IN, USA) and incubated for 30 min at 371C with shaking. The reaction was stopped by adding fetal bovine serum (FBS) to 10% final concentration. The cell suspension was filtered consequentially through 45-and 30-mm nylon mesh, centrifuged for 10 min at 300 g and washed several times. Finally, the NPC were equilibrated with OptiPrep (Accurate Chemicals & Scientific, Westbury, NY, USA) 11% final concentration and overlaid on top of 14% OptiPrep. Cells localized between 11-14% were collected and washed in HBSS, containing 5% FBS and 20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic (HEPES), pH 7.4 (Sorting buffer).
Stable oval cell line was established from D-galtreated animal on day 5 after injury. The NPC fraction was obtained as described previously 31 and after digestion with collagenase, pronase and DNAseI the cells were washed several times with Dulbecco's modified eagle medium containing 25 mM HEPES, pH 7.4, mixed with equal volume of 50% Percoll and centrifuged for 30 min at 800 g. The pellet was washed and the cells seeded sparsely: 1 Â 10 5 cells per 10-cm dish in Dulbecco's modified eagle medium supplemented with 10% FBS. After a week the oval cells formed multiple colonies with epithelial appearance that were purified by cloning rings.
Sorting of Thy1 Positive/CD45-Negative Progenitor/ Oval Cells and PDGFR-b Positive Stellate Cells NPC (60 Â 10 6 ) isolated as described above were labeled with monoclonal anti-CD45 PE conjugated antibody and monoclonal anti-Thy1 FITC conjugated antibody (both diluted 1:50 in sorting buffer) for 30 min in the cold. Appropriate controls for setting the sorting gates with the two fluorophores were run simultaneously. Sorting of the Thy1 positive/CD45 negative cells were carried out on a MoFlo high speed cell sorter (Dako North America). Viable cells were discriminated and sorted from death cells using To-Pro-3 DNA staining dye (Invitrogen). Cell viability was 75%.
PDGFR-b positive stellate cells were isolated after labeling with polyclonal anti-human PDGFR-b antibody in sorting buffer. The cells were incubated for 20 min, washed twice with sorting buffer and antirabbit IgG microbeads for MACS (Miltenyi Biotec) were added and the positive cells were collected using a MidiMACS separation unit (Miltenyi Biotec). RNA from Thy1 and PDGFR-b positive cells was isolated.
RNA Isolation and cDNA Microarrays
Total RNA was isolated from frozen liver tissues at the different time points with Trizol reagent (Invitrogen, Carlsbad, CA, USA) as described previously. 30 RNA for cDNA microarrays was isolated first with Trizol, and then additionally purified with RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). RNA integrity was checked on an Agilent 2100 Bioanalyzer. The cDNA microarray labeling reactions were carried out with 100 mg total RNA by synthesizing first-strand cDNA using a standard protocol 30 (http://microarray1k.aecom.yu.edu/). Target and reference cDNAs were labeled with Cy5 and Cy3, respectively. cDNA microarrays were obtained from the Functional Genomics Facility, Albert Einstein College of Medicine). The mouse gene chips contained 8976 clones originally obtained from Incyte Genomics (MGEM V1.0 sequence verified set). The array platform is deposited in the Gene Expression Omnibus (GEO) data repository and can be viewed or downloaded under accession number GPL409.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis and RNA Probes
All reverse transcriptase reactions were carried out with SuperScript II Reverse Transcriptase (Invitrogen), according to the manufacturer's protocol. Rat specific primers for different genes were chosen with the Primer3 program. The expression level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used in all cases as an internal control. Sequences of rat-specific primers were as follows:
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IF Microscopy
Frozen rat liver sections (5 mm) were fixed in 4% paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.3% Triton X-100, treated with sodium borohydride and blocked with 5% donkey serum, 1% bovine serum albumin (BSA). The primary anti-human Gpc3 antibodies were applied overnight at 41C in 2% donkey serum, 1% BSA and the secondary, fluorescent conjugated antibody for 40 min at room temperature. Double labeling experiments were carried out under regular blocking conditions. Sections were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Fluorescent images were taken with a Nikon Eclipse TE 2000-S fluorescent microscope or Leica AOBS confocal microscope.
Dual In Situ Hybridization and Immunohistochemistry/In Situ Hybridization Labeling
Dual in situ hybridization (ISH) and immunohistochemistry (IHC)/ISH were performed, as described previously. 27 Gpc3 riboprobe was labeled either with 35 S or with digoxigenin; AFP riboprobe was labeled with digoxigenin. For detection of the radioactive hybrids, the slides were embedded into autographic emulsion (NBT2; Kodak, Rochester, NY, USA) and exposed for 2-4 weeks. Digoxigenin labeled hybrids were detected with anti-digoxigenin-AP and antidigoxigenin-POD antibodies (Roche Applied Science). Alkaline phosphatase activity was visualized with BCIP/NBT (Roche Applied Science) and peroxidase activity was visualized with 3,3-diaminobenzidine.
For double IHC/ISH, frozen slides were first processed with CK-19 antibody and peroxidase activity from secondary anti-mouse antibody was visualized by 3,3-diaminobenzidine staining, and then ISH was performed with 35 S-labeled Gpc3 antisense riboprobe. Slides were exposed with autographic emulsion for 2-4 weeks. All slides were weakly stained with hematoxylin and eosin (H&E). Pictures were taken with a Nikon coolscope. 
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Total Protein Isolation and Western Blots
Frozen liver tissue from normal adult and 2-AAF/ PH livers at 2, 10, 16, 20 and 30 days after PH was homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS) supplemented with proteinase inhibitors, Complete Mini (Roche Applied Science). The homogenate was centrifuged for 10 min, at 10 000 g in the cold. The supernatant was transferred to a new tube and protein content measured with BCA reagent (Pierce Biotechnology, Inc., Rockford, IL, USA) for 30 min at 601C. One hundred mg of total protein was boiled for 5 min with equal volume of 2 Â loading buffer (Bio-Rad, Hercules, CA, USA) and applied on 7.5% SDS polyacrylamide gel. Fractionated proteins were transferred to PVDF membrane (Bio-Rad) by semidry transfer. The membrane was blocked in 5% nonfat milk in washing buffer (100 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 1 h at RT. Overnight incubation with primary antibodies was followed by three washes with washing buffer and incubation with secondary POD conjugated antibody. POD activity was developed with Super Signal West Femto Maximum Sensitive Substrate (Pierce Biotechnology, Inc.). The chemiluminescence was visualized on Fuji Super RX films.
Results
Expression of Gpc3 in Fetal Hepatoblasts
Using mouse cDNA microarrays we identified Gpc3 as a differentially expressed gene in fetal hepatoblasts. The expression pattern of this gene in rat fetal hepatoblasts was studied at embryonic days 13, 14, 15, 17, 18, newborn and 7 day after birth. RNA was isolated from fetal hepatoblasts and used as a tester RNA, vs newborn RNA, which served as a reference. As presented in Figure 1a , higher expression of Gpc3 was observed early in fetal life (embryonic days [13] [14] , and then it gradually decreased. To determine how long after birth Gpc3 is expressed in the liver, we carried out another experiment, in which we followed its expression in the course of several weeks after birth using RT-PCR. As shown in Figure  1b the expression of Gpc3 declined gradually and was not observed in the liver of 3-week-old animal after 26 cycles of PCR. However, expression of Gpc3 was detectable in the liver of adult animal after 36 cycles (see Figure 1b) . As fetal liver is rich in hematopoietic cells, to distinguish these cells from hepatoblasts we applied dual ISH on fetal liver sections and isolated fetal liver cells. Gpc3 mRNA was detected with radioactive ( 35 S) riboprobe and AFP was detected with digoxigenin labeled riboprobe. As shown in Figure 1c , the expression of Gpc3 is restricted only to fetal hepatoblasts ( 35 S radioactive label, grains). Its expression colocalizes with that of AFP (digoxigenin label, brown), which proves that Gpc3 it is not expressed in the hematopoietic cells (these cells do not express AFP). These experiments show that Gpc3 is highly and differentially expressed in fetal hepatoblasts and that its expression is gradually downregulated in adult liver.
Expression of Gpc3 in Hepatic Progenitor/Oval Cells
RT-PCR analysis of Gpc3 expression
To determine whether Gpc3 is also expressed in the adult hepatic progenitor cells, we studied its Gpc3 a marker of hepatic progenitor cells PN Grozdanov et al expression in models of oval cells activation and proliferation: in the liver of 2-AAF-treated animals at different time points after PH and in D-gal-treated animals at 1 through 10 days after the injection. Total RNA was extracted from the livers of these animals and subjected to RT-PCR analysis.
In both models, expression of Gpc3 was markedly increased. Maximum expression was observed on day 10 in the 2-AAF/PH model, coinciding with the highest expression of CK-19 and AFP (CK-19 and AFP are two well-known markers of oval cells, see Fausto and Campbell, 1 Dabeva and Shafritz, 2 Grisham and Thorgeirsson, 3 Alison et al, 4 Sell 5 and Roskams et al 6 ) (Figure 2a) . At 16 days after PH, the level of Gpc3 already declined and 20 days after PH the expression reached normal levels. The expression of Gpc3 was also highly increased in the D-gal model after day 3, reaching maximum on day 5, which was also the maximum for AFP expression (Figure 2b ).
To determine the protein level of Gpc3 we carried out Western blot analysis with total liver lysates from adult normal and 2-AAF/PH injured livers on day 2, 10, 16, 20 and 30 after PH (Figure 2d ). Gpc3 protein was detectable in normal liver and at day 2 after PH (100 mg of protein loaded). At day 10 and 16 Gpc3 gene products reached its maximum and then slowly decreased at day 20 and 30, but remained higher than the normal liver. These results show that both Gpc3 mRNA and protein are upregulated in the two liver injury models and when the level of mRNA returns to normal, the expression of the protein is still upregulated, most probably due to the longer half-life of this protein.
ISH analysis of Gpc3 expression
The expression of Gpc3 in hepatic progenitor/oval cells was further studied by combined dual ISH/IHC analysis on liver sections of normal and 2-AAF/PH and D-gal-treated rats, using radioactive labeled Gpc3 antisense probe and CK-19 antibody. In normal liver, few Gpc3 positive cells colocalized with CK-19 positive cholangiocytes of the bile ducts (Figure 3a) (arrow) and few others were CK-19 negative showing periductular localization (arrowhead). In the two liver injury models, the labeling with CK-19 antibody detected the oval cells forming the typical branching duct-like structures, expanding from the periportal region and invading into the parenchyma (brown color) (Figure 3b and c) . The expression of Gpc3 (grains, arrows) colocalized with the expression of CK-19 in oval cells; however, some other periductular cells that were CK-19 negative were also Gpc3 positive (grains, arrowheads). These data clearly show that Gpc3 is expressed in two subpopulations of liver oval/progenitor cells, one expressing and the other not expressing CK-19. To determine whether the second population of Gpc3 positive and CK-19 negative cells could be cells already committed to the hepatocytic lineage we performed ISH on serial sections, using digoxigenin labeled Gpc3 and AFP riboprobe, respectively, and detecting the hybrid with antidigoxigenin-AP and visualizing AP with BCIP/NBT as substrate (purple color). The results presented in Figure 3e and e 0 demonstrate that progenitor/oval cells coexpress Gpc3 and AFP and that the signals from both genes overlapped in the two sections. The presented above data show that in normal liver Gpc3 is expressed at low level in cholangiocytes and in some periductular cells and that Gpc3 expression is highly induced in activated liver progenitor/oval cells.
IF analysis of Gpc3 expression
The cellular localization of Gpc3 in normal and 2-AAF-treated animals was further studied with double IF microscopy. Gpc3 was detected with antihuman Gpc3 antibody and visualized with Cy2. Oval cells were detected with CK-19 or OV6 monoclonal antibodies against these CKs and visualized with Cy3. In preliminary experiments, we found that Gpc3 antibody also crossreacts with endothelial cells of blood vessel and sinusoids. Blocking with protein lysates from normal liver eliminates this binding (data not shown). In normal rat liver Gpc3 labeling clearly delineates the smallest CK-19 biliary ductules (Figure 4a Gpc3 a marker of hepatic progenitor cells PN Grozdanov et al negative (arrowhead). Oval cells of 2-AAF/PHtreated animals are labeled by both OV6 (which detects common epitope in CK-14 and -19 32 ), and Gpc3. While OV6 antibody labels the duct-like lumen (apical surface of the epithelial cells), Gpc3 antibody labels the basal surface, delineating the basal lamina of the pseudoducts (Figure 4b, arrows) . In addition, single Gpc3 and OV6 positive cells outside the biliary ductules are also present, as well as Gpc3 positive cells that do not express OV6 (Figure 4b, arrowheads) .
To prove further the localization of Gpc3 on the basal lamina we carried out colabeling experiments of Gpc3 and laminin. As it is shown in Figure 4f the signals from both proteins colocalize on the basal membrane.
Upon activation, oval cells proliferate in close proximity to stellate cells. 33, 34 To determine whether Gpc3 is expressed in oval cells and not in stellate cells, we performed double IF microscopy experiment using Gpc3 antibody (green color) and GFAP antibody (a marker for stellate cells, 35, 36 red color) or desmin antibody (a marker for activated stellate cells, 35, 36 red color). GAFP positive stellate cells are uniformly distributed throughout normal liver (Figure 4c ) but in the 2-AAF/PH model the GAFP marker seems less represented (Figure 4d ). In contrast, the desmin positive activated stellate cells surround proliferating oval cells and are densely packed around them. However, there is no overlap of the two labels, showing that Gpc3 is indeed expressed only in the progenitor cells and not in the stellate cells (Figure 4e, arrows) . Our results demonstrate again the intimate contact between proliferating oval cells and activated stellate cells. 37, 38 Our results show further that this heparan sulfate is located in the basal lamina of expanding oval cells, while desmin positive cells are outside surrounding the pseudoduct structures.
Expression of Gpc3 in isolated cells
To confirm that Gpc3 is expressed in oval cells we tried to isolate the cells using Gpc3 antibody. However, during the collagenase/pronase digestion, required for isolation of NPC, the protein was removed from the cell surface. Alternatively, we isolated oval cells using the procedure described by Petersen et al 39 and isolated cells that were Thy1 positive and CD45 negative. The expression pattern of these cells is presented in Figure 5a . These oval cells express AFP, CK-19 and Gpc3, but not CD45.
Pure desmin positive cells in the context of oval cells expansion could not be isolated by density gradient centrifugation as these 'activated' stellate cells sediment with the oval cells. To overcome this problem, we used antibodies against stellate cells specific surface marker PDGFR-b. 40, 41 The expression profile of the isolated stellate cells is presented in Figure 5b . These cells are positive for desmin, but negative for AFP, CK-19 and Gpc3. These results clearly show that Gpc3 is expressed in Thy1 positive oval cells and not expressed in stellate cells.
Expression of Gpc3 in Liver Lesions Induced by the SFC Protocol
Treatment of animals with 2-AAF in conjunction with PH activates Gpc3 expression in oval cells. After a month the expression of Gpc3 returns to normal. However, when the animals were treated with a single injection of the tumor initiator, diethylnitrosamine, before 2-AAF/PH, the expression of Gpc3 did not subside. Elevated expression was observed in the course of 9 months (Figure 2c) . Indeed, double IF analysis for detection of Gpc3 and CK-19 showed persistent (Gpc3 þ , CK-19 þ ) oval cell clusters after 2 months (Figure 6a ). The number of these foci increased over time and 9 months after the beginning of the experiment multiple lesions resembling oval cell duct-like structures or atypical ductular reaction were frequently observed. These atypical ductules express both CK-19 and Gpc3 (Figure 6b ), demonstrating the persistent expression of Gpc3 in liver lesions induced by the SFC protocol. Figure 6c represents IHC for CK-19 and H&E staining of a liver lesion and Figure 6d gives a micrograph of partial large cluster of H&E staining of the same paraffin embedded tissue.
Expression of Gpc3 in Cell Lines
Finally, we tested the expression of Gpc3 in an oval cell line established from the liver of Fisher 344 rats on day 5 after injection of D-gal, in a differentiated hepatoma cell line FAO-1 42 and in an epithelial cell line WB-F344 sharing phenotypic properties with oval cells. 3, 43 RNA was isolated and RT-PCR analysis was performed as described in Materials and methods. Figure 7a presents the RT-PCR analysis 44 and Dlk-1.
45
In this work, we show for the first time that in addition to AFP, Gpc3 is another oncofetal protein marker expressed in liver progenitor cells. This result was obtained with two different animal models of activation of progenitor/oval cells: 2-AAF/PH and D-gal; and by applying three independent cell and molecular analyses: RT-PCR analysis, combined ISH, IHC and IF analyses and FACS analysis of Thy1 positive oval cells. Gpc3 is expressed in morphologically distinguishable oval cell structures forming branching duct-like structures emanating from the portal region of the liver acinus. These cells coexpress the oval cell markers CK-19 and OV6. Our IF microscopy analyses show that Gpc3 is a component of the basal membrane of the oval cell pseudoducts, positioned between oval cells and stellate cells and colocalizes with laminin that delineates the basal membrane. However, Gpc3 is not expressed in the stellate cells judged from the lack of its mRNA in isolated stellate cells and from the double IF analysis for desmin and Gpc3, showing that the two proteins are not localized in the same cellular/extracellular compartment. For this reason it is likely that Gpc3 serves as receptor for signal molecules secreted by the stellate cells. In addition, Gpc3 is expressed in a second population of cells that are CK-19 negative and show periductular localization. During differentiation hepatic progenitor cells lose some of their markers and acquire others. [46] [47] [48] As Gpc3 is coexpressed with AFP, the hallmark of liver progenitor cells, we assume that the second population of periductular cells is hepatocytic progenitors. Given that Gpc3 is expressed in all hepatoblasts in fetal liver and in AFP positive and/or CK-19 positive cells of the injured livers with activation of oval cell compartment, we believe that Gpc3 is a marker for all hepatic progenitor cells.
In normal liver, few nonparenchymal cells reveal expression of Gpc3. These cells are part of small biliary epithelial structures or are single CK-19 positive cells. Other CK-19 negative cells are located in the periportal region. It is commonly believed that liver progenitor cells originate from the canals of Hering, lined by both hepatocytes and biliary ductular epithelial cells. [1] [2] [3] [4] In a few studies, when allyl alcohol was used to cause liver injuries, small intra portal 'stem' cells were reported to proliferate in response to the injury. 49, 50 Our findings show that Gpc3 is expressed in both types of cells: those located in the canals of Hering and also in cells in the periportal region that could represent the second population of progenitor cells expressing AFP and Gpc3 but not CK-19.
The expression of Gpc3 is not downregulated in animals subjected to initiation and tumor promotion, according to SFC protocol. In this protocol, proliferation of oval cells is not inhibited by 2-AAF. As a consequence of this, the initiated oval cells proliferate in response to PH forming clusters of duct-like structures that eventually enlarge into atypical hyperplastic ductular reaction. Gpc3 expression persists in the duct-like oval cell structures and in the preneoplastic lesions, expressing both CK-19 and Gpc3. The fact that oval cells continuously express Gpc3 during promotion, while changing their morphological appearance, strongly supports the idea that liver progenitor/oval cells are the origin of hepatocellular carcinoma in this model.
The exact function and mechanism of action of Gpc3 is not known. It was reported that this surface molecule modulates growth factor signaling (fibroblast growth factor-2, BMP-4, BMP-7) 14, 16, 18 and both canonical and noncanonical Wnt signaling. 17, 51 Interestingly, the expression of Gpc3 is turned on in carcinomas originating from tissues that normally do no express it, that is, hepatocellular carcinoma and melanoma. 52 In contrast, its expression is turned down in tumors originating from tissues that normally express it, that is, mammary gland 53 and lung. 54 Here, we showed that oval cells coexpress AFP/CK-19 and Gpc3. It is possible that Gpc3 terminates their growth and induces their differentiation. Such a mechanism is supported by the fact that in SGBS of Gpc3-deficient mouse model fetal cells cannot stop their proliferation and overgrowth was observed. [11] [12] [13] [14] [15] Our efforts are currently aimed at elucidation the function of Gpc3 in liver progenitor cells. Once the biological function of this proteoglycan in hepatic tissue is elucidated, it may be possible to use this master switch of proliferation/apoptosis for the benefits of the hepatic cells in disease.
